$KROS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Keros Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Keros Therapeutics, Inc.. Get notifications about new insider transactions in Keros Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 2,650 | 795 | 129,705 | |
| Jun 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 52.13 | 219 | 11,416 | 77,907 | 78.1 K to 77.9 K (-0.28 %) |
| Jun 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 51.73 | 898 | 46,454 | 78,126 | 79 K to 78.1 K (-1.14 %) |
| Jun 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 50.37 | 1,533 | 77,217 | 79,024 | 80.6 K to 79 K (-1.90 %) |
| Jun 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 2,650 | 795 | 80,557 | 77.9 K to 80.6 K (+3.40 %) |
| Jun 15 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Option Exercise | M | 0.48 | 1,000 | 480 | 98,211 | |
| Jun 15 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 51.95 | 347 | 18,027 | 0 | 347 to 0 (-100.00 %) |
| Jun 15 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 50.48 | 653 | 32,963 | 347 | 1,000 to 347 (-65.30 %) |
| Jun 15 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Buy | M | 0.48 | 1,000 | 480 | 1,000 | 0 to 1,000 |
| Jun 03 2021 | KROS | Keros Therapeutics ... | Farzan Nima | Director | Option Exercise | A | 51.48 | 8,293 | 426,924 | 8,293 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Option Exercise | M | 0.48 | 1,000 | 480 | 99,211 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Option Exercise | M | 0.48 | 1,000 | 480 | 99,211 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 50.15 | 1,000 | 50,150 | 0 | 1,000 to 0 (-100.00 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 50.15 | 1,000 | 50,150 | 0 | 1,000 to 0 (-100.00 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Buy | M | 0.48 | 1,000 | 480 | 1,000 | 0 to 1,000 |
| May 13 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Buy | M | 0.48 | 1,000 | 480 | 1,000 | 0 to 1,000 |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 500 | 150 | 7,793 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 500 | 150 | 7,793 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.11 | 6,220 | 684 | 0 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.11 | 6,220 | 684 | 0 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 2,650 | 795 | 132,355 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 2,650 | 795 | 132,355 | |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 500 | 150 | 77,907 | 77.4 K to 77.9 K (+0.65 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 500 | 150 | 77,907 | 77.4 K to 77.9 K (+0.65 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.11 | 6,220 | 684 | 77,407 | 71.2 K to 77.4 K (+8.74 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.11 | 6,220 | 684 | 77,407 | 71.2 K to 77.4 K (+8.74 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 50.00 | 2,650 | 132,500 | 71,187 | 73.8 K to 71.2 K (-3.59 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 50.00 | 2,650 | 132,500 | 71,187 | 73.8 K to 71.2 K (-3.59 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 2,650 | 795 | 73,837 | 71.2 K to 73.8 K (+3.72 %) |
| May 13 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 2,650 | 795 | 73,837 | 71.2 K to 73.8 K (+3.72 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 54.35 | 339 | 18,425 | 383,205 | 383.5 K to 383.2 K (-0.09 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 54.35 | 520 | 28,262 | 572,305 | 572.8 K to 572.3 K (-0.09 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 53.73 | 780 | 41,909 | 383,544 | 384.3 K to 383.5 K (-0.20 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 53.73 | 1,196 | 64,261 | 572,825 | 574 K to 572.8 K (-0.21 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.48 | 616 | 36,640 | 384,324 | 384.9 K to 384.3 K (-0.16 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.48 | 942 | 56,030 | 574,021 | 575 K to 574 K (-0.16 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.78 | 4,506 | 264,863 | 384,940 | 389.4 K to 384.9 K (-1.16 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.78 | 6,905 | 405,876 | 574,963 | 581.9 K to 575 K (-1.19 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.86 | 4,600 | 266,156 | 389,446 | 394 K to 389.4 K (-1.17 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.86 | 7,054 | 408,144 | 581,868 | 588.9 K to 581.9 K (-1.20 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.63 | 4,460 | 252,570 | 394,046 | 398.5 K to 394 K (-1.12 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.63 | 6,841 | 387,406 | 588,922 | 595.8 K to 588.9 K (-1.15 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.04 | 3,509 | 196,644 | 398,506 | 402 K to 398.5 K (-0.87 %) |
| May 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.04 | 5,383 | 301,663 | 595,763 | 601.1 K to 595.8 K (-0.90 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Option Exercise | M | 0.48 | 1,000 | 480 | 100,211 | |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 61.23 | 233 | 14,267 | 0 | 233 to 0 (-100.00 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 60.01 | 367 | 22,024 | 233 | 600 to 233 (-61.17 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 59.09 | 400 | 23,636 | 600 | 1,000 to 600 (-40.00 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Buy | M | 0.48 | 1,000 | 480 | 1,000 | 0 to 1,000 |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 5,300 | 1,590 | 135,005 | |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 61.72 | 100 | 6,172 | 71,187 | 71.3 K to 71.2 K (-0.14 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 61.08 | 729 | 44,527 | 71,287 | 72 K to 71.3 K (-1.01 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 59.99 | 3,473 | 208,345 | 72,016 | 75.5 K to 72 K (-4.60 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 59.10 | 998 | 58,982 | 75,489 | 76.5 K to 75.5 K (-1.30 %) |
| Apr 14 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 5,300 | 1,590 | 76,487 | 71.2 K to 76.5 K (+7.45 %) |
| Apr 08 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.95 | 35 | 2,098 | 402,015 | 402.1 K to 402 K (-0.01 %) |
| Apr 08 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.95 | 54 | 3,237 | 601,146 | 601.2 K to 601.1 K (-0.01 %) |
| Apr 08 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.10 | 2,402 | 141,958 | 402,050 | 404.5 K to 402.1 K (-0.59 %) |
| Apr 08 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.10 | 3,685 | 217,784 | 601,200 | 604.9 K to 601.2 K (-0.61 %) |
| Apr 08 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.22 | 1,233 | 71,785 | 404,452 | 405.7 K to 404.5 K (-0.30 %) |
| Apr 08 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.22 | 1,889 | 109,978 | 604,885 | 606.8 K to 604.9 K (-0.31 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.26 | 6,972 | 420,133 | 405,685 | 412.7 K to 405.7 K (-1.69 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.26 | 10,690 | 644,179 | 606,774 | 617.5 K to 606.8 K (-1.73 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.76 | 3,551 | 212,208 | 412,657 | 416.2 K to 412.7 K (-0.85 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.76 | 5,445 | 325,393 | 617,464 | 622.9 K to 617.5 K (-0.87 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.66 | 195 | 11,439 | 416,208 | 416.4 K to 416.2 K (-0.05 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.66 | 298 | 17,481 | 622,909 | 623.2 K to 622.9 K (-0.05 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.36 | 134 | 8,222 | 416,403 | 416.5 K to 416.4 K (-0.03 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.36 | 206 | 12,640 | 623,207 | 623.4 K to 623.2 K (-0.03 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.82 | 283 | 17,212 | 416,537 | 416.8 K to 416.5 K (-0.07 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.82 | 434 | 26,396 | 623,413 | 623.8 K to 623.4 K (-0.07 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.08 | 1,533 | 90,570 | 416,820 | 418.4 K to 416.8 K (-0.37 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 59.08 | 2,350 | 138,838 | 623,847 | 626.2 K to 623.8 K (-0.38 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.42 | 2,472 | 144,414 | 418,353 | 420.8 K to 418.4 K (-0.59 %) |
| Apr 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.42 | 3,790 | 221,412 | 626,197 | 630 K to 626.2 K (-0.60 %) |
| Apr 02 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.11 | 9,996 | 1,100 | 0 | |
| Apr 02 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.11 | 9,996 | 1,100 | 71,187 | 61.2 K to 71.2 K (+16.34 %) |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Option Exercise | M | 0.48 | 1,000 | 480 | 101,211 | |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 64.86 | 605 | 39,240 | 0 | 605 to 0 (-100.00 %) |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 64.09 | 395 | 25,316 | 605 | 1,000 to 605 (-39.50 %) |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Buy | M | 0.48 | 1,000 | 480 | 1,000 | 0 to 1,000 |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 5,300 | 1,590 | 140,305 | |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 65.47 | 4 | 262 | 61,191 | 61.2 K to 61.2 K (-0.01 %) |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 64.72 | 3,557 | 230,209 | 61,195 | 64.8 K to 61.2 K (-5.49 %) |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 63.99 | 1,739 | 111,279 | 64,752 | 66.5 K to 64.8 K (-2.62 %) |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 5,300 | 1,590 | 66,491 | 61.2 K to 66.5 K (+8.66 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.03 | 126 | 7,312 | 420,825 | 421 K to 420.8 K (-0.03 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.03 | 193 | 11,200 | 629,987 | 630.2 K to 630 K (-0.03 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.21 | 553 | 31,637 | 420,951 | 421.5 K to 421 K (-0.13 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.21 | 847 | 48,457 | 630,180 | 631 K to 630.2 K (-0.13 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.18 | 895 | 50,281 | 421,504 | 422.4 K to 421.5 K (-0.21 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.18 | 1,376 | 77,304 | 631,027 | 632.4 K to 631 K (-0.22 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 55.21 | 1,932 | 106,666 | 422,399 | 424.3 K to 422.4 K (-0.46 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 55.21 | 2,962 | 163,532 | 632,403 | 635.4 K to 632.4 K (-0.47 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 54.22 | 1,086 | 58,883 | 424,331 | 425.4 K to 424.3 K (-0.26 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 54.22 | 1,662 | 90,114 | 635,365 | 637 K to 635.4 K (-0.26 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.88 | 496 | 29,204 | 425,417 | 425.9 K to 425.4 K (-0.12 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.88 | 761 | 44,808 | 637,027 | 637.8 K to 637 K (-0.12 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.79 | 1,894 | 109,454 | 425,913 | 427.8 K to 425.9 K (-0.44 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.79 | 2,903 | 167,764 | 637,788 | 640.7 K to 637.8 K (-0.45 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.95 | 1,958 | 111,508 | 427,807 | 429.8 K to 427.8 K (-0.46 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.95 | 3,004 | 171,078 | 640,691 | 643.7 K to 640.7 K (-0.47 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 55.91 | 518 | 28,961 | 429,765 | 430.3 K to 429.8 K (-0.12 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 55.91 | 793 | 44,337 | 643,695 | 644.5 K to 643.7 K (-0.12 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.90 | 90 | 5,571 | 430,283 | 430.4 K to 430.3 K (-0.02 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.90 | 138 | 8,542 | 644,488 | 644.6 K to 644.5 K (-0.02 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.61 | 361 | 21,880 | 430,373 | 430.7 K to 430.4 K (-0.08 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.61 | 554 | 33,578 | 644,626 | 645.2 K to 644.6 K (-0.09 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.05 | 686 | 41,194 | 430,734 | 431.4 K to 430.7 K (-0.16 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.05 | 1,052 | 63,173 | 645,180 | 646.2 K to 645.2 K (-0.16 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.90 | 714 | 42,055 | 431,420 | 432.1 K to 431.4 K (-0.17 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.90 | 1,095 | 64,496 | 646,232 | 647.3 K to 646.2 K (-0.17 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.93 | 2,377 | 137,700 | 432,134 | 434.5 K to 432.1 K (-0.55 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.93 | 3,644 | 211,097 | 647,327 | 651 K to 647.3 K (-0.56 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 67.60 | 30 | 2,028 | 434,511 | 434.5 K to 434.5 K (-0.01 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 67.60 | 46 | 3,110 | 650,971 | 651 K to 651 K (-0.01 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 66.04 | 516 | 34,077 | 434,541 | 435.1 K to 434.5 K (-0.12 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 66.04 | 792 | 52,304 | 651,017 | 651.8 K to 651 K (-0.12 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 65.28 | 479 | 31,269 | 435,057 | 435.5 K to 435.1 K (-0.11 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 65.29 | 734 | 47,923 | 651,809 | 652.5 K to 651.8 K (-0.11 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 64.09 | 406 | 26,021 | 435,536 | 435.9 K to 435.5 K (-0.09 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 64.09 | 625 | 40,056 | 652,543 | 653.2 K to 652.5 K (-0.10 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.22 | 1,169 | 73,904 | 435,942 | 437.1 K to 435.9 K (-0.27 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.22 | 1,794 | 113,417 | 653,168 | 655 K to 653.2 K (-0.27 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 62.11 | 1,473 | 91,488 | 437,111 | 438.6 K to 437.1 K (-0.34 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 62.11 | 2,257 | 140,182 | 654,962 | 657.2 K to 655 K (-0.34 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.33 | 1,050 | 64,397 | 438,584 | 439.6 K to 438.6 K (-0.24 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.33 | 1,608 | 98,619 | 657,219 | 658.8 K to 657.2 K (-0.24 %) |
| Mar 01 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.11 | 33,200 | 3,652 | 9,996 | |
| Mar 01 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.11 | 33,200 | 3,652 | 61,191 | 28 K to 61.2 K (+118.61 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.85 | 30 | 1,916 | 450,930 | 451 K to 450.9 K (-0.01 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.85 | 46 | 2,937 | 676,148 | 676.2 K to 676.1 K (-0.01 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.14 | 531 | 33,527 | 450,960 | 451.5 K to 451 K (-0.12 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.14 | 814 | 51,396 | 676,194 | 677 K to 676.2 K (-0.12 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 62.52 | 641 | 40,075 | 451,491 | 452.1 K to 451.5 K (-0.14 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 62.52 | 985 | 61,582 | 677,008 | 678 K to 677 K (-0.15 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.03 | 913 | 55,720 | 452,132 | 453 K to 452.1 K (-0.20 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.03 | 1,397 | 85,259 | 677,993 | 679.4 K to 678 K (-0.21 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.20 | 833 | 50,147 | 453,045 | 453.9 K to 453 K (-0.18 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.20 | 1,278 | 76,936 | 679,390 | 680.7 K to 679.4 K (-0.19 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 67.98 | 35 | 2,379 | 453,878 | 453.9 K to 453.9 K (-0.01 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 67.99 | 53 | 3,603 | 680,668 | 680.7 K to 680.7 K (-0.01 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 66.65 | 206 | 13,730 | 453,913 | 454.1 K to 453.9 K (-0.05 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 66.65 | 316 | 21,061 | 680,721 | 681 K to 680.7 K (-0.05 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 65.80 | 1,575 | 103,635 | 454,119 | 455.7 K to 454.1 K (-0.35 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 65.80 | 2,418 | 159,104 | 681,037 | 683.5 K to 681 K (-0.35 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 64.87 | 952 | 61,756 | 455,694 | 456.6 K to 455.7 K (-0.21 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 64.87 | 1,461 | 94,775 | 683,455 | 684.9 K to 683.5 K (-0.21 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.83 | 1,526 | 97,405 | 456,646 | 458.2 K to 456.6 K (-0.33 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.83 | 2,335 | 149,043 | 684,916 | 687.3 K to 684.9 K (-0.34 %) |